Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...

Equities researchers at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report issued on Friday. The brokerage set a “hold” rating on the ...

Two open-access reviews by a renowned neonatal immunologist have highlighted the uniqueness of the developing infant immune ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseActive ...

Interim results show positive antibody responses were effectively induced against the target antigen at week 6 after two ...

Last revised in 2015, the document provides guidance for addressing underdiagnosis and undermanagement of the disease, as ...

Researchers developed MassiveFold, an enhanced AlphaFold version optimized for parallel processing, which accelerates protein ...

A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.

Mycoplasma Plate Antigens Market. The global mycoplasma plate antigens market, valued at USD 465 million in 2021, is set to experience robust growth, according to recent market an ...